allogeneic adipose-derived mesenchymal stem cells / Hope Biosciences - LARVOL DELTA

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Hope Biosciences | Not yet recruiting ➔ Recruiting

Enrollment open • Idiopathic Arthritis • Immunology • Rheumatology

Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury (clinicaltrials.gov) - P1/2 | N=70 | Not yet recruiting | Sponsor: Hope Biosciences | Initiation date: Jan 2025 ➔ May 2025

Trial initiation date • Acute Kidney Injury • Nephrology • Renal Disease

HBPD04: Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Hope Biosciences Stem Cell Research Foundation | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Movement Disorders • Parkinson's Disease

AKI: Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury (clinicaltrials.gov) - P1/2 | N=70 | Not yet recruiting | Sponsor: Hope Biosciences

New P1/2 trial • Acute Kidney Injury • Nephrology • Renal Disease

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis (clinicaltrials.gov) - P2 | N=66 | Not yet recruiting | Sponsor: Hope Biosciences

New P2 trial • Idiopathic Arthritis • Immunology • Rheumatology

HBPCOVID02: Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome (clinicaltrials.gov) - P2 | N=80 | Completed | Sponsor: Hope Biosciences Stem Cell Research Foundation | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

HBPCOVID02: Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: Hope Biosciences Stem Cell Research Foundation | Trial completion date: Dec 2025 ➔ Mar 2024

Trial completion date • Infectious Disease • Novel Coronavirus Disease

Safety of multiple intravenous infusions of adipose-derived mesenchymal stem cells for hospitalized cases of COVID-19: a randomized controlled trial. (PubMed, Front Med (Lausanne)) - P2 | "Multiple infusions of 100MM allogeneic HB-adMSCs were considered safe for the study population. More research is needed to determine the safety of MSC therapy. (www.ClinicalTrials.gov) identifier NCT04362189."

Journal • Fatigue • Hematological Disorders • Infectious Disease • Mood Disorders • Novel Coronavirus Disease • Pain • Psychiatry • Respiratory Diseases • CRP • IL6

HBPD04: Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Hope Biosciences Stem Cell Research Foundation | Trial completion date: Jan 2024 ➔ Jan 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

HBPCOVID02: Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: Hope Biosciences Stem Cell Research Foundation | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

HBPD04: Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Hope Biosciences Stem Cell Research Foundation | Trial completion date: Jul 2023 ➔ Jan 2024 | Trial primary completion date: Jul 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 (clinicaltrials.gov) - P2 | N=53 | Terminated | Sponsor: Hope Biosciences Stem Cell Research Foundation | N=100 ➔ 53 | Active, not recruiting ➔ Terminated; No need to continue with VACCINE available

Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8 • ICAM1 • IL10 • IL6 • Myoglobin • TNFA

HBPCOVID02: Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Hope Biosciences Stem Cell Research Foundation | Initiation date: Jan 2021 ➔ Jan 2022

Trial initiation date • Infectious Disease • Novel Coronavirus Disease

HBPCOVID02: Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome (clinicaltrials.gov) - P2; N=80; Recruiting; Sponsor: Hope Biosciences Stem Cell Research Foundation; Initiation date: Dec 2021 ➔ Jan 2021

Clinical • Trial initiation date • Infectious Disease • Novel Coronavirus Disease

HBPCOVID02: Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome (clinicaltrials.gov) - P2; N=80; Recruiting; Sponsor: Hope Biosciences Stem Cell Research Foundation

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 (clinicaltrials.gov) - P2; N=55; Completed; Sponsor: Hope Biosciences Stem Cell Research Foundation; Active, not recruiting ➔ Completed; N=100 ➔ 55

Clinical • Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease • IL10 • IL6 • TNFA

HBPD04: Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate) (PD) (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: Hope Biosciences Stem Cell Research Foundation

New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

FDA Authorizes Simultaneous Stem Cell Trials for Parkinson’s (Businesswire) - "Houston area non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received Food and Drug Administration (FDA) authorization for a Phase II clinical trial to assess the efficacy and safety of multiple intravenous infusions of allogeneic adipose-derived mesenchymal stem cells in improving activities of daily living and quality of life in subjects with Parkinson’s Disease."

New P2 trial • CNS Disorders • Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 (clinicaltrials.gov) - P2; N=100; Active, not recruiting; Sponsor: Hope Biosciences; Trial completion date: Apr 2021 ➔ Jul 2021

Clinical • Trial completion date • Infectious Disease • Novel Coronavirus Disease • IL10 • IL6 • TNFA

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Hope Biosciences; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8 • ICAM1 • IL10 • IL6 • Myoglobin • TNFA

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 (clinicaltrials.gov) - P2; N=100; Active, not recruiting; Sponsor: Hope Biosciences; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8 • ICAM1 • IL10 • IL6 • Myoglobin • TNFA

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 (clinicaltrials.gov) - P2; N=100; Active, not recruiting; Sponsor: Hope Biosciences; Enrolling by invitation ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • IL10 • IL6 • TNFA

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 (clinicaltrials.gov) - P2; N=100; Active, not recruiting; Sponsor: Hope Biosciences; Trial completion date: Oct 2020 ➔ Oct 2021; Trial primary completion date: Oct 2020 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8 • ICAM1 • IL10 • IL6 • Myoglobin • TNFA

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 (clinicaltrials.gov) - P2; N=110; Not yet recruiting; Sponsor: Hope Biosciences

Clinical • New P2 trial • Novel Coronavirus Disease • CD4 • CD8 • ICAM1 • IL10 • IL6 • Myoglobin • TNFA

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 (clinicaltrials.gov) - P2; N=100; Enrolling by invitation; Sponsor: Hope Biosciences

Clinical • New P2 trial • Novel Coronavirus Disease • IL10 • IL6 • TNFA